Abstract
Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.
Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.
Protein & Peptide Letters
Title:Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy
Volume: 24 Issue: 5
Author(s): Deasmond O. Acheampong*, Christian K. Adokoh*, Paulina Ampomah, Daniel S. Agyirifor, Isaac Dadzie, Francis A. Ackah and Ernest A. Asiamah
Affiliation:
- Department of Biomedical Sciences, School of Allied Health Sciences, University of Cape Coast, Cape Coast,Ghana
- Department of Forensic Sciences, School of Biological Sciences, University of Cape Coast, Cape Coast,Ghana
Keywords: Antibody, bispecific antibody (BsAb), immunotherapeutic agent, cancer therapy, diabody, antitumor.
Abstract: Antibodies have become the preferred therapeutic treatment option for cancers. Antibody therapy is associated with low toxic profile and specific in its activity, unlike chemotherapy and radiotherapy. Types of tumor are known to express multiple receptors that cross-talk to activate perpetual growth, proliferation and metastasis, and inhibit apoptosis in such tumors. Bispecific antibodies (BsAbs) are therefore the preferred agent for the treatment of such cancers due to its unique characteristics. This review discusses up to date therapeutic potentials of BsAbs.
Export Options
About this article
Cite this article as:
Acheampong O. Deasmond*, Adokoh K. Christian*, Ampomah Paulina, Agyirifor S. Daniel, Dadzie Isaac, Ackah A. Francis and Asiamah A. Ernest, Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy, Protein & Peptide Letters 2017; 24 (5) . https://dx.doi.org/10.2174/0929866524666170120095128
DOI https://dx.doi.org/10.2174/0929866524666170120095128 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Astatine Radiopharmaceuticals: Prospects and Problems
Current Radiopharmaceuticals HER3 and its Ligand, Heregulin, as Targets for Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Emerging Roles of P2X Receptors in Cancer
Current Medicinal Chemistry Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Thyroid Ultrasound and Other Imaging Procedures in the Pediatric Age
Current Pediatric Reviews HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design Plant Polyphenols and Tumors: From Mechanisms to Therapies, Prevention, and Protection Against Toxicity of Anti-Cancer Treatments
Current Medicinal Chemistry Therapeutic Potential and Outlook of Alternative Medicine for Osteoporosis
Current Drug Targets Tumor Escape from Immune Response: Mechanisms and Targets of Activity
Current Drug Targets Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94
Current Topics in Medicinal Chemistry TRPM6 and TRPM7: A Mul-TRP-PLIK-Cation of Channel Functions
Current Pharmaceutical Biotechnology Oncorine, the World First Oncolytic Virus Medicine and its Update in China
Current Cancer Drug Targets <i>Zanthoxylum bungeanum</i> Seed Oil Elicits Autophagy and Apoptosis in Human Laryngeal Tumor Cells via PI3K/AKT/mTOR Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry EGF-R Small Inhibitors and Anti-EGF-R Antibodies: Advantages and Limits of a New Avenue in Anticancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Zinc and Copper Homeostasis in Head and Neck Cancer: Review and Meta-Analysis
Current Medicinal Chemistry Combinations of Plant Polyphenols & Anti-Cancer Molecules: A Novel Treatment Strategy for Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Aspects of the Enzastaurin-Pemetrexed Combination in Non-Small Cell Lung Cancer (NSCLC)
Current Drug Targets Editorial (Thematic Issue: Gene Therapy for Fanconi Anemia Enters a New Clinical Era)
Current Gene Therapy